# Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients

Study · id `cardio:ct-nct04684498` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04684498](<https://clinicaltrials.gov/study/NCT04684498>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04684498

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 382 participants.

## Technical summary

Registry record NCT04684498. Randomized; no masking; primary purpose treatment. Start 2020-03-01 (actual); primary completion 2023-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 382 participants (planned count; ClinicalTrials.gov record NCT04684498, source copy `cardio:ctgov-nct04684498-2020-12-24`, retrieved 2026-10-26)
- Started: 2020-03-01 (actual) (ClinicalTrials.gov record NCT04684498, source copy `cardio:ctgov-nct04684498-2020-12-24`, retrieved 2026-10-26)
- Primary completion: 2023-06-30 (anticipated) (ClinicalTrials.gov record NCT04684498, source copy `cardio:ctgov-nct04684498-2020-12-24`, retrieved 2026-10-26)
- Completion: 2024-03-31 (anticipated) (ClinicalTrials.gov record NCT04684498, source copy `cardio:ctgov-nct04684498-2020-12-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04684498, source copy `cardio:ctgov-nct04684498-2020-12-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04684498-2020-12-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients
- Condition: ST Elevation Myocardial Infarction
- Condition: STEMI
- Intervention (Drug): Oseltamivir phosphate capsules
- Lead sponsor: Tongji Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Tongji Hospital (`cardio:org-tongji-hospital`)

## Provenance

Content hash: 886094b7c4b4f3646fa2ab93ecccfdc1e3f5d0363ebc7bba9baf256dd4835f0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
